Dr. Ansell on Promising Combinations Being Studied in MCL

Video

In Partnership With:

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

There are several clinical trials exploring combination regimens in MCL, one of which is lenalidomide (Revlimid) and rituximab (Rituxan) in the frontline setting, Ansell explains. The exciting part of this study, he adds, is that the response rates have been high in patients receiving the combination. This has also challenged researchers' thinking that they only need to use aggressive treatments.

Immunotherapy could also have potential in treating these patients, he says. The current challenge, however, is that there are little data on how well immune checkpoint therapies work in MCL. Prior clinical studies included a small portion of patients with MCL, and there has not really been an MCL-focused trial. Many trials are ongoing, so longer follow-up will determine whether this is a promising treatment, he adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,